Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neoplasm Metastasis 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Melanoma 2Lymphoproliferative Disorders 2Leukemia, Myeloid, Acute 2Glioma 2Brain Neoplasms 2Uveal Melanoma 1Thrombocytosis 1Sarcoma 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Noonan Syndrome 6 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Thyroid Cancer Patients Who Received Target Therapy × entrectinib × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡